Dr Reddy's launches fentanyl transdermal patch in India
This article was originally published in Scrip
Dr Reddy's Laboratories has launched a fentanyl transdermal patch 25μg/hr and 50μg/hr (marketed as Finrid) in India. The product has been licensed from Sparsha Pharma, an Indian transdermal products firm, and is used in the management of severe to moderate pain. Finrid provides continuous systemic delivery of fentanyl, a potent opioid analgesic, for up to 72 hours.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.